Section II
251 – 260 of 8748
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Breathe in...breathe out... How difficult can it be in patients with asthma or allergy?
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Do Not Teach the Landmark Technique for Central Venous Catheterization-Primum Non Nocere!
(
- Contribution to journal › Letter
-
Mark
Plasma matrix metalloproteinases and tissue inhibitors of metalloproteinases explored in relation to the severity and progression of diabetic retinopathy in patients with type 1 diabetes : Baseline and prospective analyses
(
- Contribution to journal › Article
-
Mark
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply
(
- Contribution to journal › Letter
-
Mark
Hospital readmissions among people with intellectual disabilities compared to the general population: a longitudinal register study (IDcare)
2024) Disability Studies Conference 2024(
- Contribution to conference › Abstract
-
Mark
Disability and long-term breathlessness : A cross-sectional, population study
(
- Contribution to journal › Article
-
Mark
Interpretative Implications of Not Adjusting for Race: : A Switch to the Global Lung Function Initiative Global Spirometry Equations
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation
2024) In Journal of Allergy and Clinical Immunology(
- Contribution to journal › Article
-
Mark
A Comparison of Brain-State Representations of Binary Neuroimaging Connectivity Data. Comment on Samantaray et al. Unique Brain Network Identification Number for Parkinson’s and Healthy Individuals Using Structural MRI. Brain Sci. 2023, 13, 1297
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
(
- Contribution to journal › Article